SPOTLIGHT -
Ms Kuntz is the assistant managing editor of Psychiatric Times.
Which Antidepressant Causes the Least Amount of Weight Gain?
New research found that among 8 first-line antidepressants, bupropion was associated with the least weight gain most consistently.
What It Means to Be a Humanitarian Celebrating the Work of H. Steven Moffic, MD
Psychiatric Times asked H. Steven Moffic, MD, to share his thoughts on humanitarianism and psychiatry.
Alzheimer Disease Treatment Donanemab Receives FDA Approval
Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.
Presenting Our July Theme: Schizophrenia
Write to us now to be part of our series focused on schizophrenia this month.
The Potential of Ketamine: Public Workshop and New Research Explores Uses
While ketamine is a not approved for the treatment of depression or chronic pain, clinicians have shown increased interest in using it for these conditions. An FDA workshop is exploring its potential.
Approved sNDA: Wakix for Treatment of Excessive Daytime Sleepiness in Youth With Narcolepsy
The FDA has approved its supplemental New Drug Application for Wakix tablets for the treatment of excessive daytime sleepiness in pediatric patients aged 6 years and older with narcolepsy.
First Nontobacco Flavored E-Cigarette Products Authorized by the FDA
The FDA has authorized the marketing of 4 menthol-flavored e-cigarette products in the United States through the premarket tobacco product application pathway.
Phase 2 Study Initiated: ALTO-101 for Cognitive Impairment With Schizophrenia
ALTO-101 has previously been shown to positively impact cognition in schizophrenia.
A Brief Cannabis Cessation Protocol to Increase Patient Motivation
Cannabis withdrawal syndrome impacts approximately half of those who use it regularly. How can you help patients cease cannabis use?
How to Safely and Effectively Taper Benzodiazepines
Review tapering challenges and strategies for benzodiazepines in this Special Report article.
Lumateperone as an Adjunctive Therapy to Antidepressants: More Positive Results
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, according to new study.
Lykos Therapeutics Releases Statement on FDA Advisory Committee Meeting
Following the vote of the US Food and Drug Administration Psychopharmacologic Drugs Advisory Committee, Lykos has released a statement on MDMA-assisted therapy.
Cannabis Facts by State
With cannabis legalization increasing in the United States, so too are the issues surrounding cannabis access, usage, and use disorders. State by state, take a peek at some of the issues and updates surrounding cannabis.
Transgender Patients: Considerations for Care
Transgender individuals are 4 times as likely as their cisgender peers to have a mental illness. Check out these culturally competent care strategies and tips to provide the best possible care.
Donanemab: FDA Advisors Unanimously Recommend for Approval
The FDA Advisory Committee recommended donanemab, which could lead to its approval later this year.
Seltorexant, Major Depressive Disorder, and Insomnia: Thoughts on the New Data
Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.
FDA Panel Votes Against MDMA-Assisted Therapy
The FDA Psychopharmacologic Drugs Advisory Committee voted against recommending approval for psychedelic MDMA.
The Role of Psychedelics in Psychiatry: A Conversation With Rachel Dalthorp, MD, MHSA
The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?
Why Clinicians Should Be Excited About Austedo XR
Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.
First Participant Dosed in Study of BPL-003 Neurophysiological Effects
Investigators have dosed the first participant in a new study investigating the neurophysiological effects of BPL-003.
A Critical Step Forward: A Clinician’s Thoughts on MDMA-Assisted Therapy
A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.
A Skeptical Look at MDMA From a PTSD Expert
Some clinicians are skeptical about the potential of MDMA-assisted therapy...
MDMA-Assisted Therapy for PTSD: A Conversation With Amy Emerson, CEO of Lykos Therapeutics
If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.
The Cutting Edge of Medicine: An Interview With Alejandro Alva, MD
In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.
Seltorexant for Major Depressive Disorder With Insomnia Symptoms Sees Positive Results
Research on MDD treatments seltorexant and Spravato (esketamine) CIII nasal spray shared at 2024 ASCP Annual Meeting.
Austedo XR Approved: A New Treatment Option for Tardive Dyskinesia and Huntington Disease
The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.
Onyda XR: The First and Only Liquid Nonstimulant ADHD Medication
Onyda XR is the first and only liquid nonstimulant ADHD medication approved in the US and the only approved nonstimulant ADHD medication with nighttime dosing.
New Research: Revealing the True Duration of Binge-Eating Disorder
Investigators at McLean Hospital found 61% and 45% of individuals still experiencing binge-eating disorder after 2.5 and 5 years after their initial diagnoses, respectively.
TerXT: Combination of Xanomeline and Trospium Prodrugs for Schizophrenia
Sam Clark, MD, PhD, the founder and CEO of Terran Biosciences shared all you need to know about the development of their schizophrenia treatment, TerXT.
Supporting the Mental Health of AAPI Youth
In honor of Asian American/Pacific Islander Heritage Month, we had a discussion on how best to support AAPI youth and their families.